|
[1]
|
Cohen, M.S. and Baden, L.R. (2012) Pre-exposure Prophylaxis for HIV—Where Do We Go from Here? New England Journal of Medicine, 367, 5. http://dx.doi.org/10.1056/NEJMe1207438
|
|
[2]
|
Thigpen, C.M., Kebaabetswe, P.M., Paxton, L.A., Smith, D.K., Rose, C.E., Segolodi, T.M., et al. (2012) Antiretroviral Pre-Exposure Prophylaxis for Heterosexual HIV Transmission in Botswana. New England Journal of Medicine, 367, 423-434. http://dx.doi.org/10.1056/NEJMoa1110711
|
|
[3]
|
Baeten, J.M., Donnell, D., Ndase, P., Mugo, N.R., Campbell, J.D., Wangisi, J., et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine, 367, 399-410.
http://dx.doi.org/10.1056/NEJMoa1108524
|
|
[4]
|
Grant, R.M., Lama, J.R., Anderson, P.L., McMahan, V., Liu, A.Y., Vargas, L., et al. (2010) Pre-Exposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine, 363, 2587-2599.
http://dx.doi.org/10.1056/NEJMoa1011205
|
|
[5]
|
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P.A., Leethochawalit, M., et al. (2013) Antiretroviral Prophylaxis for HIV Infection in Injecting Drug Users in Bangkok, Thailand (The Bangkok Tenofovir Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet, 381, 2083-2090.
http://dx.doi.org/10.1016/S0140-6736(13)61127-7
|
|
[6]
|
FDA Approves First Medication to Reduce HIV Risk.
http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM311828.pdf
|
|
[7]
|
Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., et al. (2012) Pre-Exposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine, 367, 411-422.
http://dx.doi.org/10.1056/NEJMoa1202614
|
|
[8]
|
Press Release. Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study.
http://www.avac.org/ht/a/GetDocumentAction/i/49174
|
|
[9]
|
Nichols-English, G. and Poirier, S. (2000) Optimizing Adherence to Pharmaceutical Care Plans. Journal of the American Pharmaceutical Association, 40, 475-485.
|
|
[10]
|
(2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach.
http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf
|
|
[11]
|
Clauson, K.A., Polen, H.H., Joseph, S.A. and Zapantis, A. (2009) Role of the Pharmacist in Pre-Exposure Chemoprophylaxis (PrEP) Therapy for HIV Prevention. Pharmacy Practice (Internet), 7, 11-18.
http://dx.doi.org/10.4321/S1886-36552009000100002
|
|
[12]
|
(2012) Investigator’s Brochure: Truvada® (Emtricitabine/Tenofovir Disoproxil Fumarate) Tablets. Gilead Sciences, Foster City.
|
|
[13]
|
CDC (2011) Characteristics Associated with HIV Infection among Heterosexuals in Urban Areas with High AIDS Prevalence—24 Cities, United States, 2006-2007. MMWR, 60, 1045-1049.
|
|
[14]
|
(2012) Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults. MMWR, 61, 586-589.
|
|
[15]
|
(2013) Proven HIV Methods. Centers for Disease Control and Prevention.
http://www.cdc.gov/nchhstp/newsroom/docs/HIVFactSheets/Methods-508.pdf
|
|
[16]
|
Santschi, V., Chiolero, A., Burnand, B., Colosimo, A.L. and Paradis, G. (2011) Impact of Pharmacist Care in the Management of Cardiovascular Disease Risk Factors: A Systematic Review and Meta-Analysis of Randomized Trials. Archives of Internal Medicine, 171, 1441-1453. http://dx.doi.org/10.1001/archinternmed.2011.399
|